<DOC>
	<DOCNO>NCT00002717</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know chemotherapy regimen effective ovarian peritoneal cancer . PURPOSE : Randomized phase III trial compare effectiveness two regimen paclitaxel plus cisplatin treating patient residual disease surgery remove stage III stage IV ovarian cancer primary peritoneal cancer .</brief_summary>
	<brief_title>Paclitaxel Cisplatin Treating Patients With Stage III Stage IV Ovarian Cancer Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare progression free overall survival frequency response patient suboptimal stage III IV ovarian epithelial cancer primary peritoneal cancer treat 24 hour v 96 hour infusion paclitaxel ( TAX ) follow cisplatin . II . Determine incidence severity adverse event , include catheter complication drug toxicity , 96 hour infusion TAX . III . Compare relationship plasma TAX concentration , toxicity , response infusion schedule patient population . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center measurable disease ( yes v ) . Patients randomize one two treatment arm . Arm I : Patients receive paclitaxel IV continuously 24 hour follow cisplatin IV 2 hour . Arm II : Patients receive paclitaxel IV continuously 96 hour follow cisplatin IV 2 hour . Treatment repeat every 3 week 6 course . PROJECTED ACCRUAL : A total 324 patient accrue study 4.5 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary ovarian epithelial cancer primary peritoneal cancer Suboptimal residual disease within 6 week laparotomy maximum resection Stage III residual retroperitoneal disease great 1 cm great 1 cm residual intraperitoneal disease OR Stage IV disease The following histology eligible : Serous adenocarcinoma Malignant Brenner 's tumor Mucinous adenocarcinoma Endometrioid adenocarcinoma Undifferentiated carcinoma Clear cell adenocarcinoma Mixed epithelial carcinoma Transitional cell carcinoma Adenocarcinoma otherwise specify Measurable disease require Cytologic confirmation malignant pleural effusion require sole basis entry No borderline ( low malignant potential ) carcinoma No unclassified ovarian cancer , i.e. , think ovarian origin unexplored unable verify tumor arise ovarian stroma PATIENT CHARACTERISTICS : Age : 18 Performance status : GOG 02 Hematopoietic : WBC least 3,000/mm3 Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time normal AST , ALT , GGT great 3 time normal Alkaline phosphatase great 3 time normal LDH great 3 time normal No acute hepatitis Renal : Creatinine great 2 mg/dL Cardiovascular : No history congestive heart failure No history unstable angina No myocardial infarction within 6 month Other : No severe infection , include septicemia No severe gastrointestinal bleeding No history second malignancy within 5 year except nonmelanomatous skin cancer Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior cytotoxic chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics No 6 week since stag laparotomy primary cytoreductive surgery</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>ovarian undifferentiated adenocarcinoma</keyword>
	<keyword>ovarian mixed epithelial carcinoma</keyword>
	<keyword>ovarian serous cystadenocarcinoma</keyword>
	<keyword>ovarian mucinous cystadenocarcinoma</keyword>
	<keyword>ovarian endometrioid adenocarcinoma</keyword>
	<keyword>ovarian clear cell cystadenocarcinoma</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
	<keyword>Brenner tumor</keyword>
</DOC>